Antibiotic Side Effect, Obesity, Childhood
Conditions
Keywords
Microbiome, Antibiotics, Growth
Brief summary
This cross-disciplinary study will assemble and longitudinally follow a large, diverse birth cohort to determine the relationships between early life antibiotic exposure, microbiome development, growth, antibodies, and immunostimulation.
Detailed description
Perinatal and infant antibiotic exposures are common and have been linked to changes in the gut microbiome, which plays a central role in health and disease. Childhood obesity is an epidemic and animal models have linked antibiotic induced changes in the microbiome with increased adiposity. Infants become colonized with trillions of bacteria in the first few hours of life. During this time period, their nascent immune system develops tolerance to commensal microbes The primary objectives are to measure the impact of common perinatal and early childhood antibiotic exposures on the structure and function of the developing gut microbiome. To determine the association between common perinatal and early childhood antibiotic exposures and weight/adiposity gain in a large birth cohort of children. To determine mechanisms for the association between microbiome changes over time and the rate of weight/adiposity gain in a large birth cohort of children. To determine the normal developmental pattern by which healthy children develop antibodies in their blood against the microbes that naturally colonize their intestines. To determine the association between immunostimulation and protection from persistent colonization in humans.
Interventions
None listed
Sponsors
University of Minnesota
University of Pennsylvania
National Institute of Allergy and Infectious Diseases (NIAID)
Children's Hospital of Philadelphia
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 96 Hours
Healthy volunteers
No
Inclusion criteria
(if not specified, applies to child): * Born at Pennsylvania Hospital * Recruited at \<120 hours of age * Born at ≥36 0/7 weeks gestation * Birth weight ≥2000 grams * Parents plan to receive well-child care in the Children's Hospital of Philadelphia (CHOP) network, Society Hill Pediatrics, Center City Pediatrics, Penn Medicine or South Philly Pediatrics * Biological mother is the legal guardian, or the child is born from a surrogacy with guardianship immediately transferred in hospital
Exclusion criteria
(if not specified, applies to child): * Child in neonatal intensive care unit (NICU) for \>120 cumulative hours * Biological mother NOT legal guardian, except surrogacy where guardianship is transferred at birth * Biological mother NOT primary caretaker, except surrogacy where guardianship is transferred at birth * Biological mother \< 18 years of age * Child has culture confirmed (blood or cerebrospinal fluid cultures) infection * Biological mother is non-English speaking
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cumulative microbial diversity | 24 months |
| weight trajectory adjusted for time varying length | 24 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| fat stores in the upper arm/extremity | 24 months | Skinfolds at the triceps are measured (0.1 mm) with a skinfold caliper |
| fat stores in the upper back/trunk | 24 months | Skinfolds at the superiliac and subscapular sites are measured (0.1 mm) with a skinfold caliper |
| total number of individual bacterial taxa | 24 months | — |
| determine the association between immunostimulation and protection from persistent colonization in humans | 24 months | — |
| Use autologous serum antibodies to tag fecal microbes | 24 months | — |
| supine length trajectory | 24 months | — |
| expression levels of bacterial gene categories | 24 months | — |
Countries
United States
Outcome results
None listed